VIRTUAL ONCOLOGY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Virtual Oncology Market, By Component (Software, Service, Hardware), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Others (Pancreatic, Ovarian, etc.)), By Application (Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management, Others (Billing Management, Regulatory Compliance etc.)), By End User (Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations (CROs), Others (Reference Laboratories, Pharmacies etc.)), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Recent Developments:

New product launches:

On October 2, 2023, European Commission-initiated European Cancer Imaging Initiative, (EUCAIM) and the European Commission announced the first public release of its platform, Cancer Image Europe, in the project’s development. The first platform release brings benefits to researchers, clinicians, and AI innovators across Europe and paves the way for the future of cancer diagnosis and treatment.
On September 21, 2023, Belong.Life, a global healthtech provider of high-engagement patient communities and care platforms, announced the launch of Tara, software-as-a-service (SaaS)-based conversational artificial intelligence (AI) cancer clinical trial matching platform.
In November 2022, Roche Products (India) Pvt. Ltd., a subsidiary of F. Hoffmann-La Roche Ltd, announced the launch of a mobile patient app for those taking part in its cancer support program. A new companion mobile app called Blue Tree 2.0 is improving access to the services of this program. Roche India developed the app together with smart technology company MOURI Tech.

Acquisition and partnerships:

On September 11, 2023, Dell Technologies, a technology company, announced a partnership with University of Limerick (UL) to develop an AI platform that uses digital twin technology with cancer patient data to improve diagnosis and treatment capabilities.
On September 20, 2023, Merck KGaA, a biotechnology company, announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts. The partnerships, with BenevolentAI, London, U.K., and Exscientia, Oxford, U.K., are expected to generate several novel clinical development drug candidates with first-in-class and best-in-class potential in key therapeutic areas of oncology, neurology, and immunology.
On July 18, 2023, Massive Bio, Inc., a biotechnology company, announced a partnership with CureMatch, Inc., a software company, to improve access to cancer clinical trials and precision oncology treatments through their decision support and artificial intelligence platforms. The partnership will combine CureMatch's decision support platform, which identifies cancer treatments for patients based on their molecular tumor profile, with Massive Bio's AI platform to process patient data from the CureMatch reports and match patients to clinical trials.